natgillin/translations-raw huggingface dataset:
Ar represents a phenyl group, a naphthyl group, a 5-membered or 6-membered aromatic heterocyclic group having one or two elements selected from S, N, and O, or a condensed aromatic heterocyclic group formed between a benzene ring and a 5-membered or 6-membered heterocyclic ring having one or two elements selected from S, N, and O (wherein the phenyl, naphthyl, or aromatic heterocyclic groups may be substituted by 1 to 3 halogen atoms, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group); 
Ar predstavlja fenilnu skupinu, naftilnu skupinu, 5-članu ili 6-članu aromatsku heterocikličku skupinu koji ima jedan ili dva elementa odabrana između S, N, i O, ili kondenziranu aromatsku heterocikličku skupinu formiranu između benzenskog prstena i 5-članog ili 6-članog heterocikličkog prstena koji ima jedan ili dva elementa odabrana između S, N, i O (pri čemu fenil, naftil, ili aromatske heterocikličke skupine mogu biti supstituirane s 1 do 3 atoma halogena, C1 do C6 alkil skupinom, ili C1 do C6 alkoksi skupinom);
A pharmaceutical composition comprising a compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof, and at least one of: a carrier, diluent, and excipient 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7, ili njegovu farmaceutski prihvatljivu sol, enantiomer, racemat, dijastereomer ili smjesu dijastereomera, kao i najmanjo jedno od sljedećeg: podlogu, razrjeđivač i pomoćnu tvar.
A composition for use of claim 1, having a viscosity of at least 100 mPa.s measured at 20 to 25 degrees Celsius with a shear rate of 15 sec-1. 
Stabilni oralni farmaceutski pripravak za upotrebu prema zahtjevu 1 naznačen time da ima viskoznost od najmanje 5 cP kod 25°C uz brzinu smicanja oko 13,2 sec-1.
a retro-, an inverso- or a retro-inverso variant of the amino acid sequence of (a); or a pharmaceutically acceptable salt or solvate thereof. 
retro-, inverzo- ili retro-inverzo varijantu sekvence aminokiseline pod a); ili njezinu farmaceutski prihvatljivu sol ili solvat.
Selectivity refers to the ability of the resin to interact with and bind the protein of interest. 
Selektivnost se odnosi na sposobnost smole da interagira tj. da veže željeni protein.
Certain embodiments are directed to a method of blocking or preventing attachment of P. aeruginosa to epithelial cells comprising contacting a mixture of epithelial cells and P. aeruginosa with the binding molecule or fragment thereof, the antibody or fragment thereof, the composition, the polynucleotide, the vector, or the host cell described herein. 
Protutijelo prema bilo kojem od zahtjeva 1-5 1 11 ili pripravak prema zahtjevu 6 naznačeno time daje za uporabu za blokiranje 1li sprječavanje spajanja P. aeruginosa na epitelne stanice, pri čemu se smjesa epitelnih stanica 1 P. aeruginosa dovodi u kontakt s protutijelom ili pripravkom.
The fuel was made from 90% PCB-G activated carbon and 10% SCMC. 
Gorivo je napravljeno iz 90% PCB-G aktiviranog ugljika 1 10% NKMC.
Furthermore, the biologically degradable composite material can preferably be characterised in that the collagen of the at least one organic component (c) is of animal origin, preferably of porcine or bovine origin. 
Biološki razgradivi kompozitni materijal prema bilo kojem od zahtjeva 1 do 13, naznačen time, da je kolagen životinjskog podrijetla, poželjno svinjskog ili goveđeg.
In case the material of the sealing member is the same as the one used for the capsule (e.g. a metal such as aluminum or plastics), preferably the resilient nature of the sealing member is procured by the geometrical shape of the sealing member. In the embodiment according to Fig. 2 the sealing member 8 is resiliently deflectable due to the lip-shaped form. 
U slučaju da je materijal elementa za nepropusno zatvaranje isti kao i onaj koji se koristi za čahuru (na primjer metal, kao što je aluminij, ili plastika) poželjno je da je element za nepropusno zatvaranje po prirodi elastičan, kao što je definirano u patentnim zahtjevima, i da se nabavi u geometrijskom obliku elementa za nepropusno zatvaranje.
Structure HPLC Retention Time (in minutes) 
Struktura HPLC vrijeme retencije (u|(M+ HY minutama)
The sclerostin-binding antibody of claim 1 having heavy chains of SEQ ID NO: 145 or 392 and light chains of SEQ ID NO: 141. 
Protutijelo za vezanje sklerostina iz patentnog zahtjeva 1, naznačeno time, da ima teške lance SEQ ID NO: 145 ili 392 i lake lance SEQ ID NO: 141.
TABLE 6a pH stability of Alkaloid (nicotine) containing Lozenges with Phosphate Buffer stored at 25° C./60% RH. 
Tabela 6a pH stabilnost tableta koje sadrže alkaloid (nikotin) sa fosfatnim puferom čuvane na 252C/60% relativne vlažnosti
The antisense oligonucleotide of any one of claims 1-4, wherein the oligonucleotide is chemically linked to one or more moieties or conjugates that enhance the activity, cellular distribution, or cellular uptake of the antisense oligonucleotide. 
Antisens oligonukleotid u skladu sa zahtjevom 1, naznačen time što navedeni antisens oligonukleotid je kemijski vezan na jedan ili više ostataka ili konjugata koji poboljšavaju aktivnost, raspodjelu po stanici ili unos u stanicu antisens oligonukleotida.
the transforming growth factor alpha and the epidermal growth factor marker gene, 
- < marker-genom alfa faktora transformacije rasta i marker-genom faktora epidermalnog rasta,
The method according to claim 4, wherein the volume of the new mass to be treated is smaller than the combined volume of the mixer and the grinding device. 
Postupak u skladu s patentnim zahtjevom 3, naznačen time što je volumen nove mase koju treba obraditi manji od kombiniranog volumena miješalice i naprave za mljevenje.
Use according to claim 10, in which said FISH assay is carried out according to a protocol comprising the steps of: loading a cell sample into the microchannel of the microfluidic device of claims 1 to 8; 
Uporaba prema zahtjevu 10, gdje se FISH analiza provodi prema protokolu koji obuhvaća korake: a) postavljanje staničnog uzorka u mikrokanal mikrofluidnog uređaja prema zahtjevima 1 do 8; b) ostavljanje stanica da se inkubiraju; c) fiksiranje stanica otopinom alkohola i slabe karboksilne kiseline; d) ispiranje otopinom soli natrijevog citrata (SSC);
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the extended release matrix formulation after having been stored at 25°C and 60 % relative humidity (RH), preferably at 40°C and 75 % relative humidity (RH), for at least 1 month provides a dissolution rate, when measured in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37°C, characterized by the percent amount of active agent released at 1, 4 and 12 hours of dissolution that deviates no more than about 15 % points from the corresponding in-vitro dissolution rate of a reference formulation prior to storage. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, pri čemu formulacija matrice s produljenim otpuštanjem nakon što je skladištena pri 25 °C i 60 % relativne vlažnosti zraka barem 1 mjesec daje stupanj otapanja, kad je mjerena u USP uređaju (koš) pri 100 rpm u 900 ml simulirane želučane tekućine bez prisustva enzima (SGF) pri 37 °C, naznačen time da je postotna količina aktivnog agensa oslobođena pri 1, 4 ili 12 sati otapanja koja odstupa ne više od oko 15 % točaka od odgovarajuće in-vitro stupnja otapanja referentne formulacije prije skladištenja.
In a particularly preferred embodiment of the invention, however, the pharmaceutical composition comprises at least two peptides consisting of amino acid sequences according to SEQ ID NO:1 to SEQ ID NO:12. 
Farmaceutski sastav prema zahtjevu 1, koji nadalje uključuje najmanje jedan dodatni peptid koji sadrži slijed aminokiselina odabranog iz skupine koja se sastoji od SEQ ID NO 1 te SEQID NO 4 do SEQ ID NO 12.
obtaining a solution E by adjusting the solution D to become more acidic, and heating followed by cooling; and concentrating the solution E under reduced pressure and filtration; and wherein said acute ischemic cerebrovascular disease is selected from the group consisting of cerebral embolism, transient cerebral ischemia attack, cerebral thrombosis, cerebral arteriosclerosis, cerebral arteritis, steal syndrome of cerebral artery, cranial venous sinus and venous thrombus. 
Analgecine za uporabu kao lijek za liječenje akutne ishemijske cerebrovaskularne bolesti, gdje se nakon ishemije moždanog tkiva analgecine koristi za zaštitu živčanih stanica od ozljede ili za smanjenje razine mliječne kiseline u moždanom tkivu ili za povećanje aktivnosti superoksid dismutaze, i gdje se akutna ishemijska cerebrovaskularna bolest odabire iz skupine koju čine cerebralna embolija, tranzitna cerebralna ishemijska ataka, cerebralna tromboza, cerebralna arterioskleroza, cerebralni arteritis, sindrom krađe cerebralne arterije, kranijalni venski sinus i venski tromb.
The compound of claim 5 wherein R1 is methyl, ethyl, F, Cl, cyano, CF3, or cyclopropyl; and R2 is methoxy, or ethoxy. 
Spoj u skladu s patentnim zahtjevom 5, naznačen time što je metil, etil, F, Cl, cijano, CF3 ili ciklopropil; i
a CDRH1 sequence that corresponds to amino acid residues 31 to 35 (NYVMH) of SEQ ID NO: 35, wherein one of these amino acid residues is optionally a different amino acid residue; 
(i) CDRHI sekvencu koja odgovara aminokiselinskim ostacima 31 do 35 (NYVMRH) iz SEK ID BR: 35, gdje jedan od ovih aminokiselinskih ostataka je po izboru različit aminokiselinski ostatak;
is a nitrogen atom, or is a methine group optionally substituted by a halogen atom, a hydroxyl group, a lower alkyl group or a hydroxy-lower alkyl group; 
je atom dušika, ili je metin skupina po izboru supstituirana halogen atomom, hidroksil skupinom, nižom alkilnom skupinom ili hidroksi-nižom alkilnom skupinom;
The anti-FOLR1 antibody or anti-FOLR1 immunoconjugate for use of claim 1, wherein the subject has a cancer selected from the group consisting of: ovarian cancer, endometrial cancer, cancer of the peritoneum, or lung cancer. 
Protutijelo protiv FOLRI ili imunokonjugat protiv FOLRI, namijenjeni upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što subjekt ima a rak koji se bira iz skupine koju čine: rak jajnika, rak endometrija, rak potrbušnice ili rak pluća.
Solution for obtaining a freeze-dried formulation, comprising at least one cephalosporin derivative as an active ingredient, at least one stabilizer selected from the group consisting of mannitol, trehalose and PVP in an aqueous solution. Method for preparing a stabilized freeze-dried pharmaceutically acceptable formulation for cephalosporin derivatives, comprising the steps of 
Otopina namijenjena dobivanju formulacije osušene smrzavanjem, naznačena time što sadrži najmanje jedan cefalosporinski derivat kao aktivni sastojak, gdje cefalosporinski derivat je spoj formule I, kao što je definirana u patentnom zahtjevu 1, i stabilizator, koji je manitol, u vodenoj otopini.
Embodiment 66: A pharmaceutical composition comprising a monoclonal antibody according to any of embodiments 1 to 45 or an immunoconjugate according to any of embodiments 62 to 65 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži antitijelo prema bilo kojem zahtjevu od 1 do 8, imunokonjugat prema zahtjevu 13 ili bispecifičnu ili multispecifičnu molekulu prema zahtjevu 14 ili 15 te farmaceutski prihvatljiv nosač.
treating the compound of formula (8): or a pharmaceutically acceptable salt thereof, with a compound of formula (9): or a pharmaceutically acceptable salt thereof, under suitable conditions to provide the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a single stereoisomer or enantiomer or a mixture thereof. 
[image], ili njegovom farmaceutski prihvatljivom solju, u uvjetima pogodnim za dobivanje spoja formule (I), ili njegove farmaceutski prihvatljive soli, u obliku pojedinačnog stereoizomera ili enantiomera ili njihove smjese.
The beehive has a take off board attached to its bottom with a folding mechanism allowing it to open and close. 
Košnica ima dasku koja se može skinuti i koja je pričvršćena pri dnu s preklopnim mehanizmom koji omogućuje da se ona otvori i zatvori.
The pharmaceutical composition of (a) or (b), further comprising an effective amount of an anti-HIV agent selected from the group consisting of HIV antiviral agents, immunomodulators, and anti-infective agents. 
PA: ze) ili njegove farmaceutski prihvatljive soli 1 farmaceutski prihvatljiv nosač 1 dalje sadrži efikasnu količinu anti-HIV sredstva izabranog iz grupe koja se sastoji od HIV antivirusnih sredstava, imunomodulatora i anti-infektivnih sredstava.
According to another embodiment the invention relates to the method defined hereinabove, wherein the at least one inorganic colloidal binding agent is added to the product A by mixing. 
proizvod B koji sadrži najmanje jedno anorgansko koloidno vezivno sredstvo, navedena vlakna otporna na toplinu su staklena vlakna, silicijska vlakna ili njihova smjesa, i navedeni pripravak je u termoset fazi.
recovery of the solid precipitated in step d), to give the crystalline form A of SAG. 
C) = izolacija krutine istaložene u koraku d), čime se dobiva SAG kristaliničnog oblika A.
In a particularly preferred embodiment of the invention, the present light stabilising composition has a colour intensity at 610 nm that does not exceed 0.024, preferably does not exceed 0.01 as calculated herein. 
U naročito poželjnom ostvarenju izuma, sadašnji pripravak za stabiliziranje na svjetlo ima intenzitet boje pri 610 nm koji ne prelazi 0,024, poželjno ne prelazi 0,01, kako je ovdje izračunato.
The residue was purified by column chromatography on silica gel with ethyl acetate/hexanes 2/3 to afford compound 7g (82 mg, 72%) as a white solid. 
Ostatak se pročisti kromatografijom na stupcu silikagela, uz eluiranje smjesom etilacetat/heksani 2:3 kako bi se dobilo spoj 7 g (82 mg, 72 %) u obliku bijele krutine.
A compound according to claim 1, wherein the compound is 2-(2,5-dimethylthiophen-3-yl)-4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 2-(2,5-dimetiltiofen-3-il)-4,5-dihidroksi izoftalo nitril.
An injection assembly according to claim 1, wherein the head (532) has a main surface (534), facing the inlet opening (506'), consisting of a truncated-cone surface with a rounded vertex. 
Injekcijski sklop u skladu s patentnim zahtjevom 12, naznačen time što glava (532) ima glavnu površinu (534), okrenutu prema ulaznom otvoru (506’), koju čini površina u obliku krnjeg stošca sa zaobljenim vrhom.
The compositions described herein can be administered to an individual (such as human) via various routes, including, for example, intravenous, intra-arterial, intraperitoneal, intrapulmonary, oral, inhalation, intravesicular, intramuscular, intra-tracheal, subcutaneous, intraocular, intrathecal, transmucosal, and transdermal. 
Pripravak za upotrebu prema patentnom zahtjevu 1, naznačen time što postupak obuhvaća davanje pripravka putem intravenoznog, intraarterijskog, intraperitonealnog, intravezikularnog, potkožnog, mtratekalnog, intrapulmonalnog, intramuskularnog, intratrahealnog, intraokularnog, transdermalnog, oralnog ili mnhalacijskog puta primjene.
represents a single or a double bond depending on X1 and X2; when R5′ is not H, N-acylating a compound of Formula (iv) wherein R5′ or N-acylating a compound of Formula (v), with a compound of Formula (vi) 
N-aciliranje spoja Formule (iv), pri čemu R5’ nije H ili spoja Formule (v), sa spojem Formule (vi) [image] pri čemu su R1, R1’, R2, R2’ i R3 onakvi kao što je definirano u zahtjevu 1;
expressing the recombinant nucleic acids of steps (b) and (c); wherein the mammalian cell does not overexpress Y-carboxylase; 
(c) eksprimiranje nukleinskih kiselina iz koraka (a) i (b); pri čemu se količina sekrecije rekombinantno eksprimiranog VKD-proteina uglavnom povećava u usporedbi s ekspresijom rVKD-proteina u organizmu domačina, koji ne ko-eksprimira VKORC1.
As mentioned above, the key process steps for formation of IL-2/SDS microaggregates are (a) the addition and then (b) subsequent removal of SDS. 
Kako je navedeno gore, ključni stupnjevi procesa za oblikovanje mikroagregata IL-2/SDS su (a) dodavanje i zatim (b) naredno odstranjivanje SDS.
A syringe assembly 2 according to any preceding claim, wherein the medicament is selected from a group of medicaments consisting of: analgesics, anti-convulsants, antidepressants, vasodilators, steroids, opiate antagonists, anaesthetics, antiadrenergic compounds, antiallergic drugs, anti-anginals, anti-asthmatics, antibacterials, anti-coagulants, anti-cholinergics, antiemetics, antiepileptics, antihistaminics, antiinfectives, antiinflammatories, antimigraine drugs, bronchodilators, cardiac depressants, thrombolitics, beta blockers, opioids, sedatives, benzodiazepines and stimulants. 
Set za špricu 2 prema bilo kojem prethodnom zahtjevu, pri čemu lijek spada u jednu od sljedećih grupa lijekova: analgetici, antikonvulzivi, antidepresivi, vazodilatori, steroidi, antagonisti opijata, anestetici, antiadrenergički spojevi, antialergijski lijekovi, antianginalni lijekovi, antiastmatici, antibakterijski lijekovi, antikoagulansi, antiholinergici, antiemetici, antiepileptici, antihistaminici, antiinfektivi, antiinflamatorici, antimigrenici, bronhodilatatori, sedativi za srce, trombolitici, beta blokeri, opioidi, sedativi, benzodiazepini i stimulansi.
colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), oesophageal cancer, oral squamous carcinoma, tongue carcinoma, gastric carcinoma, nasopharyngeal cancer, hematopoietic tumours of lymphoid lineage (e.g. 
kolorektalnog karcinoma, kao što su, primjerice, adenokarcinomi debelog crijeva i adenomi debelog crijeva), raka jednjaka, oralnog planocelularnog karcinoma, karcinoma jezika, karcinoma želuca, karcinoma nazofarinksa, hematopostskih tumora limfnih čvorova (npr.
Visual inspection: Breach of the enamel surface and 
Vizualna inspekcija: napuknute površine cakline i obezbojenje.
17.7 Total coated Tablet 
17.7 Ukupno obložena tableta
dissolving poly alpha-1,3-glucan in a solvent to make a poly alpha-1,3-glucan solution; 
otapanje poli alfa-1,3-glukana u otapalu kako bi se dobila otopina poli alfa-1,3-glukana;
The system according to claim 9, further including an air handling unit, such that the first water circulating system further includes a heat transfer portion for projecting a pipe section encapsulating a flow of the cooled water into an air current within said air handling unit. 
Sustav u skladu s patentnim zahtjevom 9, naznačen time što dodatno uključuje jedinicu za obradu zraka, tako da prvi sustav za kruženje vode (9) dodatno sadrži dio za prijenos topline radi ispružanja dijela cijevi koji okružuje protok ohlađene vode u struju zraka unutar navedene jedinice za obradu zraka.
The process according to claim 11 wherein said aprotic solvent is N,N-dimethylformamide. 
Postupak prema patentnom zahtjevu 11 gdje navedeno aprotonsko otapalo jest N,N-dimetilformamid.
The composition of claim 3 wherein the surfactant is polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 60 hydrogenated castor oil, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl 40 stearate, polyoxyl 150 stearate, polyoxyl 150 distearate, d-a-tocopheryl polyethylene glycol 1000 succinate, poloxamer 124, poloxamer 188, poloxamer 407, sorbitan monolauryl ester, sorbitan monopalmityl ester, sorbitan monostearyl ester, or a mixture of any two or more thereof. 
Sastav prema patentnom zahtjevu 3, naznačen time, da površinski aktivna tvar jest polioksil 35 ricinusovo ulje, polioksil 40 hidrirano ricinusovo ulje, polioksil 60 hidrirano ricinusovo ulje, polisorbat 20, polisorbat 40, polisorbat 60, polisorbal 80, polioksil 40 stearal, polioksil 150 stearal, polioksil 150 distearat, d-a-tokoferil polietilen glikol 1000 sukcinat, poloksamer 124, poloksamer 188, poloksamer 407, sorbitan monolauril ester, sorbitan monopalmitil ester, sorbitan monostearil ester, ili smjesa od bilo kojeg od dvoje ili od više njih.
A compound selected from: and, or a pharmaceutically acceptable salt thereof. 
HR P20181774 T1 PATENTNI ZAHTJEVI 1. = Spoj selektiran iz:
The fraction may contain some r-hIL-18BP in case of column overloading. 
Frakcija može sadržavati i malo r-hIL-18BP u slučaju ako se na kolonu nanese previše uzorka.
determining, by the source eNB, that there is no user data packet to be sent to the target eNB in a data sending buffer,, and sending, by the source eNB, the special data packet generated by the source eNB to the target eNB; 
Postupak prema bilo kojem zahtjevu od 1 do 3, naznačen time da, kada target eNB prosljeđuje pakete korisničkih podataka isporučene od SGW prema UE nakon prijema posebnog paketa podataka od izvorišnog eNB, ciljni eNB ne prosljeđuje poseban paket podataka prema UE.
The conjugate of claim 1 or 2, wherein the tumour marker is a tumour antigen, and wherein the tumour antigen is optionally carcinoembryonic antigen (CEA) 
Konjugat prema zahtjevu 1 ili 2, naznačen time da je tumorski marker tumorski antigen, i pri čemu je tumorski antigen po potrebi karcinoembrijski antigen (CEA).
or delays the transmission or forwarding of a considered data packet, wherein the first network node (101) comprises a first decision policy information (105) comprising at least one first decision parameter and a first logic and/or first rules and the telecommunications network (100) is configured such that the given communication situation of one data packet or a plurality of data packets is avoided by means of 
- Ili odgađa prijenos ili prosljeđivanje razmatranog paketa podataka, pri čemu prvo mrežno čvorište (101) sadrži prvu informaciju smjera odlučivanja (105) koji se sastoji od barem jednog parametra prve odluke 1 prva logična i/ili prva pravila tako da dana komunikacijska situacija jednog paketa podataka ili više paketa podataka se izbjegava pomoću,
The compound according to clause 1, wherein said compound has formula (VI): wherein 
Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu (III):
The expression vector of claim 4, wherein the polynucleotide encoding the optimized FeLV ENV polypeptide has at least 99% sequence identity to the sequence as set forth in SEQ ID NO:3, and the polynucleotide encoding FeLV GAG/PRO polypeptide has the sequence as set forth in SEQ ID NO: 10 or 11. 
Sastav prema bilo kojem od prethodnih zahtjeva, naznačen time, da polinukleotid koji kodira ENV polipeptid za FeLV, ima najmanje 70% identiteta sekvence od sekvence prikazane u SEQ ID NO: 1, 3 ili 5, te polinukleotid koji kodira GAG/PRO polipeptid za FeLV, ima najmanje 70% identitea sekvence od sekvence prikazane u SEQ ID NO: 10ili 11.
The term “particle size” is intended to mean the shortest dimension of the particulate material in question. 
Namjera je da termin "veličina čestice" označuje najkraću dimenziju određenog materijala.
[Paragraph 13] A microorganism introduced with the vector of paragraph 12. 
Mikroorganizam uveden sa vektorom iz zahtjeva 12.
The forming method according to any of the claims from 16 to 18, characterised in that the process air treatment step comprises, at the end of the socket forming time and only during the time for cooling the material of the end (20) of the pipe (2), activation, after the cooling sub-step, of a sub-step of enriching the process air with pressurised nebulised water which in turn comprises the following steps: 
Postupak oblikovanja prema bilo kojem od zahtjeva od 14 do 16, naznačen time da korak obrade zraka za postupak sadrži, na kraju vremena oblikovanja čahure i samo tijekom vremena za hlađenje završetka (20) cijevi (2), a nakon pod-koraka hlađenja, aktivaciju pod-koraka obogaćivanja zraka za postupak sa raspršenom vodom u obliku magle pod tlakom koji se nadalje sastoji od slijedećih koraka: